

Correction: PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases *In Vitro* and *In Vivo*

In this article (Clin Cancer Res 2016;22:5818–28), which was published in the December 1, 2016, issue of *Clinical Cancer Research* (1), contributions for two authors were mistakenly omitted from the Authors' Contributions section of the published article. Tobias Sinnberg should be listed under "Conception and design" and "Development of methodology," and Heike Niessner should be listed under "Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases)." The authors regret this error.

Reference

1. Niessner H, Schmitz J, Tabatabai G, Schmid AM, Calaminus C, Sinnberg T, et al. PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases *in vitro* and *in vivo*. Clin Cancer Res 2016;22:5818–28.

Published online March 1, 2017.

doi: 10.1158/1078-0432.CCR-16-3165

©2017 American Association for Cancer Research.

Clinical Cancer Research

Correction: PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases *In Vitro* and *In Vivo*

Clin Cancer Res 2017;23:1361.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/23/5/1361>

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/23/5/1361.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/23/5/1361>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.